2003
DOI: 10.1128/cdli.10.1.70-77.2003
|View full text |Cite
|
Sign up to set email alerts
|

Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia

Abstract: The efficacy of alpha interferon (IFN-␣) in the treatment of severe type II essential mixed cryoglobulinemia (EMC) has been reported previously. In some patients, the development of neutralizing antibodies to recombinant IFN-␣ (rIFN-␣) can affect the clinical response achieved with rIFN-␣; a second treatment with natural IFN-␣ preparations may reinduce the clinical response. In the present study the ability of leukocyte IFN (LeIFN) to restore the response was investigated from a pharmacodynamic viewpoint. Spec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
14
0
2

Year Published

2005
2005
2014
2014

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(18 citation statements)
references
References 40 publications
2
14
0
2
Order By: Relevance
“…Consistent with previous reports [Ronnblom et al, 1992;Scagnolari et al, 2003], the neutralizing anti-IFN antibodies of patient P#9 cross-reacted with other IFN-a subtypes suggesting that the presence of neutralizing antibodies to IFN-a in this patient decreased IFN-a bioactivity and prevented treatment response. By contrast, IFN-b was not neutralized by the serum from patient P#9 (data not shown) suggesting IFN-b as an alternative to IFN-a in treatment of anti-IFN-a antibody positive patients.…”
Section: Discussionsupporting
confidence: 77%
“…Consistent with previous reports [Ronnblom et al, 1992;Scagnolari et al, 2003], the neutralizing anti-IFN antibodies of patient P#9 cross-reacted with other IFN-a subtypes suggesting that the presence of neutralizing antibodies to IFN-a in this patient decreased IFN-a bioactivity and prevented treatment response. By contrast, IFN-b was not neutralized by the serum from patient P#9 (data not shown) suggesting IFN-b as an alternative to IFN-a in treatment of anti-IFN-a antibody positive patients.…”
Section: Discussionsupporting
confidence: 77%
“…Antibody titres were determined, as described previously, by a neutralization test against 10 IU/mL of IFN‐α [11,12]. Different IFN‐α preparations were used: IFN‐α 2a (Roferon ® ; Hoffman‐La Roche); IFN‐α 2b (Intron ® ; Schering‐Plough), LE‐IFN‐α (Alfaferone ® ; Alfa Wassermann); Multiferon ® (Swedish Orphan Biovitrum, Stockholm, Sweden) and subtypes of IFN‐α (PBL Biomedical Laboratories, Piscataway, NJ, USA).…”
Section: Methodsmentioning
confidence: 99%
“…However, therapeutic autologous proteins often elicit antibody responses in nonautoimmune hosts . These responses reduce their efficacy , and in some instances, produce severe pathology . Degradation, modification, or aggregation of the protein , or its contamination with TLR ligands , are some of the possible factors responsible for inducing these antibody responses, although the underlying mechanisms are poorly understood.…”
Section: Introductionmentioning
confidence: 99%